Mutations or deletions in TP53 in cancers result in the upregulation of both glucose transporters and HK2 and glycolysis by expression of glycolytic enzymes, like PGM, and inhibition of Tumor Protein 53-Induced Glycolysis and Apoptosis Regulator (TIGAR) (DeBerardinis, 2008). Here, HK2 is linked to cancer.